论文部分内容阅读
目的观察阿托伐他汀对急性冠状动脉综合征(ACS)患者早期炎症因子和心脑血管事件的干预效果。方法将53例ACS患者随机分为阿托伐他汀治疗组(n=29)和常规对照组(n=24)。阿托伐他汀治疗组在对照组常规治疗基础上加用阿托伐他汀20mg,每晚1次顿服。所有患者分别于入院24h内和治疗后1个月清晨空腹采血1次,测定血脂、hs-CRP、MMP-9。同时观察6个月随访期内主要心脑血管终点事件的发生。结果治疗4周后,阿托伐他汀治疗组与对照组相比,患者TC、TG、hs-CRP及MMP-9浓度显著降低(均P<0.01),而对照组治疗前后差异无统计学意义(P>0.05)。阿托伐他汀治疗组6个月随访期内复发性心绞痛、心律失常、心力衰竭及非致命性心肌梗塞等均较常规对照组明显降低(P<0.05)。结论阿托伐他汀早期治疗ACS能够抑制炎症因子并降低半年随访期间主要心血管事件的发生率。
Objective To observe the effect of atorvastatin on early inflammatory factors and cardiovascular events in patients with acute coronary syndrome (ACS). Methods 53 ACS patients were randomly divided into atorvastatin group (n = 29) and control group (n = 24). Atorvastatin treatment group in the control group on the basis of conventional treatment plus atorvastatin 20mg, Dayton nightly service. All patients were admitted to hospital within 24 h and 1 month after treatment, 1 fasting blood sampling 1 time, serum lipids, hs-CRP, MMP-9. At the same time observe the main follow-up period of 6 months cardiovascular and cerebrovascular end point occurred. Results After 4 weeks of treatment, the levels of TC, TG, hs-CRP and MMP-9 in atorvastatin group were significantly lower than those in control group (all P <0.01), but there was no significant difference in the control group before and after treatment (P> 0.05). Recurrent angina pectoris, arrhythmia, heart failure and non-fatal myocardial infarction were all significantly lower in the atorvastatin group than those in the control group at the 6-month follow-up (P <0.05). Conclusions Early treatment with atorvastatin can inhibit inflammatory cytokines and reduce the incidence of major cardiovascular events during the follow-up period of six months.